Xavier Joseph Caro, MD
Rheumatology · Northridge
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 53 years
- University of California, San Francisco School of Medicine, 1973
Offices
1 location
Looking this up.
Hospitals listed: Northridge Hospital Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Caro’s office at (818) 993-1025 to ask if they take your plan before you enroll.
California Medical Board record
Licence G28544 · Current
Licensed to practise in California · since 1974 · expires 2027-05-31 · University of California San Francisco School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Northridge Hospital Medical CenterNorthridge, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 3 of 5 · 66% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.11, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.147, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.173, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for Northridge Hospital Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 3 better, 4 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.11 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.147 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.173 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.13 (0.13 to 2.13) · 1,012 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.78 (0.44 to 1.11) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.43 (96.43 to 190.42) · 88 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.2 · 40 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.2 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.4 · 216 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8 · 457 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.4 · 384 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 315 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 3,091 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.25 (0.05 to 0.44) · 6,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 6,139 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.59 (0.47 to 4.71) · 1,225 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.57 (0 to 3.24) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.28 to 3.34) · 1,193 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.26 (0 to 15.07) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.14 (2.11 to 10.16) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.65 (0.17 to 3.14) · 163 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.76) · 5,578 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.2 · 139 cases | None | Apr 2023 – Mar 2025 |
| SSI - Colon SurgeryInfections | 1.041 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.1 · 368 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.6 · 674 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 27.2 · 214 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 26.2 · 563 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 23.8 · 438 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17 · 484 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.9 (3.1 to 7.4) · 44 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.9 (6.8 to 13.8) · 44 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5 · 166 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 14.9 · 57 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.8 · 141 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 165 cases | No different | Jan 2024 – Dec 2024 |
What patients said (621 patients answered, 15% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 69% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 72% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 71% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 39% |
| "YES", patients would definitely recommend the hospital | 66% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$789,768
Medicare paid this office $789,768 for 66 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 22 | $368,625 | None |
| Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 13 | $99,109 | None |
| Long return visit (40+ min) | 60 | $47,839 | $149 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 34 | $29,865 | $56 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 34 | $27,171 | $18 |
See all 15 services
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 22 | $368,625 | None |
| Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 13 | $99,109 | None |
| Long return visit (40+ min) | 60 | $47,839 | $149 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 34 | $29,865 | $56 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 34 | $27,171 | $18 |
| Injection, infliximab, excludes biosimilar, 10 mg | 12 | $18,507 | None |
| Administration of chemotherapy into vein, 1 hour or less | 20 | $12,272 | $113 |
| Administration of chemotherapy into vein, each additional hour | 20 | $7,010 | $24 |
| Injection of drug or substance under skin or into muscle | 36 | $3,198 | $12 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 32 | $2,392 | None |
| New patient visit (60+ min) | 13 | $2,356 | $181 |
| Infusion, normal saline solution, 250 cc | 40 | $328 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 15 | $72 | None |
| Urinalysis, manual test | 11 | $68 | $3 |
| Injection, ketorolac tromethamine, per 15 mg | 14 | $59 | None |
Procedures Medicare counted
| Skin biopsy | 14 | More than 61% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Punch biopsy, each additional skin growth | 22 | – | – | 28 | 38 | – |
| Punch biopsy, first skin growth | 11 | – | – | 14 | 18 | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
66 Original Medicare patients in 2024. Average age 71 · Women 59% · Also on Medicaid 33% · Health risk score 2.34. Sicker patients than 9 in 10 peers; the typical rheumatology clinician is at 1.38.
Conditions among them: High blood pressure 75% · Diabetes 65% · Coronary heart disease 39% · Depression 29% · Chronic kidney disease 23% · Heart failure 21% · COPD 20%.
The office billed $3,002,195, Medicare allowed $995,236 and paid $789,768; for 28,152 services of 29 kinds; $657,898 of it was for drugs given in the office and $131,870 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 66 | 28,152 | 71 | 2.34 | $3,002,195 | $789,768 |
| 2023 | 64 | 48,771 | 69 | 2.26 | $5,892,575 | $1,699,312 |
| 2022 | 61 | 22,559 | 70 | 2.07 | $2,679,833 | $858,503 |
| 2021 | 67 | 13,721 | 70 | 2.02 | $1,409,616 | $458,270 |
| 2020 | 72 | 14,310 | 69 | 2.07 | $1,515,112 | $452,950 |
| 2019 | 73 | 19,142 | 70 | 2.14 | $1,435,423 | $458,890 |
| 2018 | 72 | 72,011 | 71 | 2.51 | $4,478,628 | $1,409,684 |
| 2017 | 67 | 91,949 | 69 | 2.24 | $5,513,682 | $1,596,235 |
| 2016 | 88 | 135,500 | 72 | 2.06 | $7,773,787 | $2,374,949 |
| 2015 | 99 | 150,688 | 70 | 2.07 | $7,956,272 | $2,387,377 |
| 2014 | 91 | 166,826 | 71 | 1.64 | $6,237,391 | $1,922,264 |
| 2013 | 103 | 104,471 | 70 | 1.66 | $6,809,263 | $2,196,591 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 18 services
| Injection, immune globulin (bivigam), 500 mg | 15 | $822,110 | None |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 23 | $256,270 | None |
| Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 17 | $92,088 | None |
| Injection, tocilizumab, 1 mg | 11 | $57,385 | None |
| Long return visit (40+ min) | 58 | $54,393 | $146 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 33 | $36,220 | $58 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 33 | $24,528 | $18 |
| Administration of chemotherapy into vein, 1 hour or less | 25 | $10,997 | $120 |
| Injection of drug or substance under skin or into muscle | 38 | $5,286 | $12 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 36 | $3,796 | None |
| Administration of chemotherapy into vein, each additional hour | 21 | $3,722 | $25 |
| New patient visit (60+ min) | 17 | $3,026 | $178 |
| Punch biopsy, first skin growth | 17 | $2,064 | $115 |
| Punch biopsy, each additional skin growth | 18 | $2,038 | $54 |
| Infusion, normal saline solution, 250 cc | 36 | $207 | None |
| Urinalysis, manual test | 20 | $198 | $3 |
| Injection, ketorolac tromethamine, per 15 mg | 25 | $183 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 21 | $177 | None |
2022: 15 services
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 19 | $175,791 | None |
| Long return visit (40+ min) | 59 | $53,755 | $137 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 29 | $36,041 | $62 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 29 | $28,874 | $19 |
| Injection of drug or substance under skin or into muscle | 41 | $6,425 | $12 |
| Administration of chemotherapy into vein, 1 hour or less | 12 | $4,980 | $128 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 38 | $3,913 | None |
| New patient visit (60+ min) | 14 | $2,459 | $176 |
| Administration of chemotherapy into vein, each additional hour | 11 | $2,134 | $27 |
| Punch biopsy, first skin growth | 13 | $1,650 | $118 |
| Punch biopsy, each additional skin growth | 13 | $1,533 | $55 |
| Infusion, normal saline solution, 250 cc | 30 | $255 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 22 | $212 | None |
| Urinalysis, manual test | 15 | $210 | $3 |
| Injection, ketorolac tromethamine, per 15 mg | 20 | $170 | None |
2021: 14 services
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 16 | $126,138 | None |
| Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 15 | $83,060 | None |
| Long return visit (40+ min) | 64 | $57,870 | $129 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 27 | $32,703 | $68 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 26 | $26,375 | $20 |
| Administration of chemotherapy into vein, 1 hour or less | 16 | $8,928 | $133 |
| Injection of drug or substance under skin or into muscle | 45 | $5,499 | $12 |
| Administration of chemotherapy into vein, each additional hour | 15 | $4,071 | $28 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 41 | $3,531 | None |
| New patient visit (60+ min) | 13 | $2,108 | $162 |
| Urinalysis, manual test | 21 | $386 | $3 |
| Infusion, normal saline solution, 250 cc | 32 | $297 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 28 | $210 | None |
| Injection, ketorolac tromethamine, per 15 mg | 19 | $112 | None |
2020: 16 services
| Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 14 | $159,270 | None |
| Long return visit (40+ min) | 66 | $43,588 | $110 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 25 | $27,863 | $65 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 23 | $22,239 | $20 |
| Administration of chemotherapy into vein, 1 hour or less | 11 | $6,305 | $131 |
| Injection of drug or substance under skin or into muscle | 54 | $5,276 | $12 |
| New patient visit (60+ min) | 25 | $4,222 | $162 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 48 | $3,661 | None |
| Administration of chemotherapy into vein, each additional hour | 11 | $2,893 | $28 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 17 | $2,537 | $70 |
| Return visit (30+ min) | 16 | $2,433 | $81 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 27 | $834 | $20 |
| Urinalysis, manual test | 19 | $283 | $3 |
| Infusion, normal saline solution, 250 cc | 28 | $239 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 31 | $158 | None |
| Injection, ketorolac tromethamine, per 15 mg | 24 | $102 | None |
2019: 22 services
| Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 11 | $109,844 | None |
| Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 11 | $70,876 | None |
| Long return visit (40+ min) | 58 | $41,505 | $123 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 26 | $28,519 | $64 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 20 | $18,742 | $19 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 44 | $10,277 | $66 |
| Injection of drug or substance under skin or into muscle | 54 | $8,709 | $14 |
| Administration of chemotherapy into vein, 1 hour or less | 11 | $7,274 | $130 |
| Return visit (30+ min) | 26 | $4,363 | $89 |
| New patient visit (60+ min) | 24 | $3,930 | $164 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 48 | $3,010 | None |
| Administration of chemotherapy into vein, each additional hour | 11 | $2,845 | $28 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 43 | $1,331 | $18 |
| Punch biopsy, first skin growth | 11 | $1,237 | $112 |
| Punch biopsy, each additional skin growth | 11 | $1,211 | $55 |
| Urinalysis, manual test | 27 | $740 | $3 |
| Injection, methylprednisolone acetate, 80 mg | 28 | $575 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 31 | $247 | None |
| Injection, ketorolac tromethamine, per 15 mg | 31 | $183 | None |
| Infusion, normal saline solution, 250 cc | 29 | $171 | None |
| Insertion of needle into vein for collection of blood sample | 16 | $129 | $3 |
| Injection, lidocaine hcl for intravenous infusion, 10 mg | 13 | $51 | None |
2018: 24 services
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 13 | $409,930 | None |
| Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 17 | $297,871 | None |
| Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg | 11 | $63,239 | None |
| Long return visit (40+ min) | 61 | $40,607 | $125 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 32 | $40,546 | $66 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 25 | $19,980 | $19 |
| Return visit (30+ min) | 45 | $13,784 | $87 |
| Injection of drug or substance under skin or into muscle | 57 | $12,479 | $18 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 43 | $12,243 | $65 |
| Administration of chemotherapy into vein, 1 hour or less | 14 | $11,221 | $129 |
| Administration of chemotherapy into vein, each additional hour | 14 | $4,182 | $28 |
| New patient visit (60+ min) | 20 | $3,573 | $179 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 47 | $3,041 | None |
| Extended office or other outpatient service, first hour | 17 | $2,347 | $112 |
| Biopsy of single growth of skin and/or tissue | 16 | $1,588 | $88 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 41 | $1,447 | $18 |
| Urinalysis, manual test | 33 | $1,020 | $3 |
| Biopsy of each additional growth of skin and/or tissue | 16 | $854 | $27 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 46 | $430 | None |
| Insertion of needle into vein for collection of blood sample | 24 | $279 | $3 |
| Injection, ketorolac tromethamine, per 15 mg | 29 | $242 | None |
| Infusion, normal saline solution, 250 cc | 32 | $124 | None |
| Red blood cell sedimentation rate, to detect inflammation, non-automated | 19 | $107 | $4 |
| Injection, lidocaine hcl for intravenous infusion, 10 mg | 17 | $39 | None |
2017: 23 services
| Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg | 14 | $657,854 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 11 | $197,300 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 32 | $45,529 | $62 |
| Long return visit (40+ min) | 56 | $31,297 | $121 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 24 | $28,289 | $17 |
| Return visit (30+ min) | 46 | $19,881 | $91 |
| Injection of drug or substance under skin or into muscle | 58 | $15,947 | $23 |
| Administration of chemotherapy into vein, 1 hour or less | 14 | $12,145 | $125 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 44 | $11,870 | $67 |
| Neuropsychological testing, interpretation, and report by psychologist or physician per hour | 12 | $5,380 | $79 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 50 | $3,580 | None |
| Administration of chemotherapy into vein, each additional hour | 14 | $3,437 | $25 |
| Biopsy of single growth of skin and/or tissue | 21 | $2,404 | $92 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 44 | $1,387 | $17 |
| Biopsy of each additional growth of skin and/or tissue | 21 | $1,371 | $29 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 46 | $788 | None |
| Urinalysis, manual test | 30 | $758 | $3 |
| Red blood cell sedimentation rate, to detect inflammation, non-automated | 29 | $730 | $5 |
| Insertion of needle into vein for collection of blood sample | 31 | $480 | $3 |
| Manual urinalysis test with examination using microscope, non-automated | 30 | $358 | $4 |
| Infusion, normal saline solution, 250 cc | 35 | $325 | None |
| Injection, ketorolac tromethamine, per 15 mg | 21 | $206 | None |
| Injection, lidocaine hcl for intravenous infusion, 10 mg | 12 | $32 | None |
2016: 34 services
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 19 | $990,590 | None |
| Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg | 15 | $398,268 | None |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 15 | $273,025 | None |
| Injection, tocilizumab, 1 mg | 11 | $205,600 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 12 | $160,503 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 36 | $66,686 | $62 |
| Long return visit (40+ min) | 74 | $39,652 | $119 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 24 | $36,925 | $17 |
| Return visit (30+ min) | 61 | $27,311 | $88 |
| Injection of drug or substance under skin or into muscle | 71 | $22,919 | $22 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 59 | $13,988 | $70 |
| Neuropsychological testing, interpretation, and report by psychologist or physician per hour | 14 | $6,406 | $81 |
| Administration of chemotherapy into vein, 1 hour or less | 13 | $6,260 | $112 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 66 | $4,308 | None |
| Extended office or other outpatient service, first hour | 35 | $4,113 | $82 |
| New patient visit (60+ min) | 21 | $3,688 | $176 |
| Biopsy of single growth of skin and/or tissue | 25 | $2,600 | $90 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 52 | $2,356 | $10 |
| Manual urinalysis test with examination using microscope, non-automated | 64 | $2,178 | $4 |
| Administration of chemotherapy into vein, each additional hour | 12 | $1,828 | $25 |
| Red blood cell sedimentation rate, to detect inflammation, non-automated | 56 | $1,646 | $5 |
| Biopsy of each additional growth of skin and/or tissue | 25 | $1,543 | $27 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 54 | $1,486 | $17 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 55 | $1,172 | None |
| Insertion of needle into vein for collection of blood sample | 56 | $932 | $3 |
| X-ray of knee, 4 or more views | 12 | $840 | $35 |
| X-ray of foot, minimum of 3 views | 14 | $694 | $26 |
| X-ray of hand, 2 views | 13 | $602 | $23 |
| X-ray of lower and sacral spine, 2-3 views | 17 | $529 | $31 |
| Injection, ketorolac tromethamine, per 15 mg | 39 | $445 | None |
| X-ray of upper spine, 2-3 views | 15 | $442 | $29 |
| Infusion, normal saline solution, 250 cc | 41 | $421 | None |
| X-ray of pelvis, 1-2 views | 12 | $340 | $28 |
| Injection, lidocaine hcl for intravenous infusion, 10 mg | 14 | $31 | None |
2015: 26 services
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 23 | $1,394,524 | None |
| Injection, tocilizumab, 1 mg | 15 | $236,367 | None |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 18 | $187,285 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 45 | $67,066 | $62 |
| Long return visit (40+ min) | 83 | $40,216 | $120 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 33 | $39,621 | $17 |
| Return visit (30+ min) | 69 | $29,752 | $89 |
| Injection of drug or substance under skin or into muscle | 78 | $20,960 | $22 |
| Neuropsychological testing, interpretation, and report by psychologist or physician per hour | 18 | $9,130 | $83 |
| Administration of chemotherapy into vein, 1 hour or less | 11 | $8,104 | $116 |
| Biopsy of single growth of skin and/or tissue | 41 | $4,081 | $89 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 72 | $3,975 | None |
| Extended office or other outpatient service, first hour | 30 | $3,749 | $85 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 72 | $3,204 | $10 |
| New patient visit (60+ min) | 17 | $2,798 | $165 |
| Manual urinalysis test with examination using microscope, non-automated | 79 | $2,519 | $4 |
| Biopsy of each additional growth of skin and/or tissue | 40 | $2,443 | $27 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 15 | $2,233 | $74 |
| Administration of chemotherapy into vein, each additional hour | 11 | $2,081 | $25 |
| Red blood cell sedimentation rate, to detect inflammation, non-automated | 75 | $1,562 | $5 |
| Insertion of needle into vein for collection of blood sample | 79 | $1,020 | $3 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 47 | $829 | None |
| Injection, ketorolac tromethamine, per 15 mg | 42 | $359 | None |
| Infusion, normal saline solution, 250 cc | 51 | $353 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 15 | $288 | $17 |
| Injection, lidocaine hcl for intravenous infusion, 10 mg | 14 | $47 | None |
2014: 30 services
| Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 12 | $463,812 | None |
| Injection, tocilizumab, 1 mg | 27 | $335,346 | None |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 18 | $308,254 | None |
| Injection, immune globulin, (gammaplex), intravenous, non-lyophilized (e.g., liquid), 500 mg | 12 | $260,555 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 43 | $48,883 | $61 |
| Long return visit (40+ min) | 84 | $42,937 | $120 |
| Return visit (30+ min) | 71 | $30,289 | $87 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 25 | $28,757 | $16 |
| Administration of chemotherapy into vein, 1 hour or less | 36 | $17,163 | $111 |
| Injection of drug or substance under skin or into muscle | 81 | $14,727 | $22 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 86 | $6,011 | $10 |
| Extended office or other outpatient service, first hour | 27 | $4,542 | $84 |
| Biopsy of single growth of skin and/or tissue | 38 | $3,746 | $89 |
| New patient visit (60+ min) | 21 | $3,401 | $162 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 75 | $3,386 | None |
| Administration of chemotherapy into vein, each additional hour | 11 | $3,364 | $25 |
| Manual urinalysis test with examination using microscope, non-automated | 84 | $2,931 | $4 |
| Red blood cell sedimentation rate, to detect inflammation, non-automated | 86 | $2,669 | $5 |
| Biopsy of each additional growth of skin and/or tissue | 38 | $2,329 | $28 |
| Insertion of needle into vein for collection of blood sample | 85 | $1,849 | $3 |
| X-ray of knee, 4 or more views | 11 | $862 | $39 |
| X-ray of foot, minimum of 3 views | 12 | $684 | $29 |
| X-ray of hand, 2 views | 13 | $649 | $25 |
| X-ray of lower and sacral spine, 2-3 views | 16 | $550 | $32 |
| X-ray of chest, 2 views, front and side | 14 | $383 | $27 |
| X-ray of upper spine, 2-3 views | 11 | $356 | $32 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 30 | $307 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 12 | $263 | $18 |
| Infusion, normal saline solution, 250 cc | 50 | $243 | None |
| Injection, ketorolac tromethamine, per 15 mg | 40 | $189 | None |
2013: 40 services
| Unclassified biologics | 11 | $529,145 | None |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 13 | $509,121 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 14 | $306,615 | None |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 19 | $229,290 | None |
| Injection, tocilizumab, 1 mg | 18 | $141,512 | None |
| Long return visit (40+ min) | 91 | $48,648 | $118 |
| Administration of chemotherapy into vein, 1 hour or less | 44 | $47,957 | $126 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 18 | $38,358 | $67 |
| Return visit (30+ min) | 77 | $35,675 | $86 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 18 | $35,381 | $19 |
| Injection of drug or substance under skin or into muscle | 88 | $16,512 | $22 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 99 | $8,257 | $11 |
| Extended office or other outpatient service, first hour | 41 | $6,654 | $81 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 87 | $6,173 | None |
| Administration of chemotherapy into vein, each additional hour | 19 | $5,323 | $27 |
| Red blood cell sedimentation rate, to detect inflammation, non-automated | 100 | $3,906 | $5 |
| Biopsy of single growth of skin and/or tissue | 34 | $3,438 | $90 |
| Manual urinalysis test with examination using microscope, non-automated | 100 | $3,399 | $4 |
| New patient visit (60+ min) | 19 | $3,143 | $165 |
| Insertion of needle into vein for collection of blood sample | 99 | $2,562 | $3 |
| Biopsy of each additional growth of skin and/or tissue | 34 | $2,060 | $27 |
| X-ray of knee, 4 or more views | 28 | $2,016 | $40 |
| X-ray of foot, minimum of 3 views | 30 | $1,650 | $29 |
| Short return visit (20+ min) | 14 | $1,442 | $63 |
| X-ray of hand, 2 views | 30 | $1,416 | $24 |
| Pneumococcal vaccine, 23-valent | 13 | $1,124 | $70 |
| X-ray of shoulder, minimum of 2 views | 21 | $1,120 | $28 |
| X-ray of lower and sacral spine, 2-3 views | 27 | $879 | $33 |
| X-ray of chest, 2 views, front and side | 31 | $818 | $26 |
| X-ray of upper spine, 2-3 views | 22 | $709 | $32 |
| X-ray of pelvis, 1-2 views | 23 | $602 | $26 |
| Administration of pneumococcal vaccine | 13 | $456 | $28 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 17 | $394 | $18 |
| Administration of influenza virus vaccine | 13 | $372 | $29 |
| Injection, ketorolac tromethamine, per 15 mg | 39 | $227 | None |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | 13 | $186 | $14 |
| Infusion, normal saline solution, 250 cc | 42 | $181 | None |
| 5% dextrose/water (500 ml = 1 unit) | 24 | $126 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 21 | $115 | None |
| Skin test for tuberculosis | 11 | $80 | $7 |
Medicaid work
$0 in 2024
Medicaid paid $0 for 33 billed services this clinician did in 2024, up to 17 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| PSYCHOTHERAPY W/PATIENT 30 MINUTES | 33 | $0 |
| 2024 | 33 | 1 | 17 | $0 |
Drugs they prescribed that Part D paid
$3,621,358
Pharmacies billed $3,621,358 in 2024. Most of that is two immune-globulin drugs at $15,000–$18,000 a fill for a small number of people.
This is pharmacy cost, not the office bill, and not what patients paid.
534 generic and 418 brand-name prescriptions · $3,621,358 in drug cost · 16 antibiotic prescriptions to 13 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Octagam | Immune globulin | 122 | $1,852,845 | $15,187 |
| Gammagard Liquid | Immune globulin | 39 | $713,775 | $18,302 |
| Remicade | None | 70 | $293,627 | $4,195 |
| Orencia | None | 49 | $211,972 | $4,326 |
| Actemra | None | 56 | $174,968 | $3,124 |
See all 17 drugs
| Octagam | Immune globulin | 122 | $1,852,845 | $15,187 |
| Gammagard Liquid | Immune globulin | 39 | $713,775 | $18,302 |
| Remicade | None | 70 | $293,627 | $4,195 |
| Orencia | None | 49 | $211,972 | $4,326 |
| Actemra | None | 56 | $174,968 | $3,124 |
| Inflectra | None | 31 | $122,948 | $3,966 |
| Methotrexate | None | 157 | $2,724 | $17 |
| Ibandronate | None | 12 | $1,962 | $163 |
| Azathioprine | None | 36 | $1,409 | $39 |
| Celecoxib | None | 20 | $1,083 | $54 |
| Hydroxychloroquine Sulfate | None | 33 | $887 | $27 |
| Prednisone | None | 88 | $525 | $6 |
| Alendronate | None | 28 | $166 | $6 |
| Allopurinol | None | 18 | $121 | $7 |
| Gabapentin | None | 11 | $110 | $10 |
| Diphenhydramine | None | 12 | $34 | $3 |
| Pantoprazole | None | 11 | $33 | $3 |
Year by year
| 2024 | 952 | 62 | None | 44% | $3,621,358 |
| 2023 | 713 | 57 | None | 32% | $1,932,285 |
| 2022 | 699 | 50 | None | None | $2,361,943 |
| 2021 | 744 | 47 | None | 36% | $2,860,167 |
| 2020 | 818 | 52 | None | 32% | $1,890,709 |
| 2019 | 857 | 52 | None | 43% | $2,541,080 |
| 2018 | 722 | 48 | None | None | $658,431 |
| 2017 | 708 | 46 | None | 32% | $337,236 |
| 2016 | 645 | 47 | None | None | $309,593 |
| 2015 | 748 | 52 | 4% (28) | None | $324,676 |
| 2014 | 660 | 53 | 4% (24) | None | $273,694 |
| 2013 | 647 | 66 | 6% (38) | None | $110,236 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 16 drugs
| Octagam | Immune globulin | 57 | $843,380 | $14,796 |
| Gammagard Liquid | Immune globulin | 21 | $364,552 | $17,360 |
| Orencia | None | 40 | $167,180 | $4,180 |
| Actemra | None | 34 | $119,037 | $3,501 |
| Inflectra | None | 26 | $112,952 | $4,344 |
| Methotrexate | None | 132 | $4,020 | $30 |
| Mycophenolate Mofetil | None | 12 | $1,723 | $144 |
| Prednisone | None | 90 | $1,242 | $14 |
| Celecoxib | None | 12 | $1,039 | $87 |
| Hydroxychloroquine Sulfate | None | 26 | $869 | $33 |
| Azathioprine | None | 24 | $595 | $25 |
| Alendronate | None | 35 | $340 | $10 |
| Allopurinol | None | 21 | $287 | $14 |
| Methylprednisolone Sodium Succ | None | 11 | $285 | $26 |
| Gabapentin | None | 12 | $90 | $8 |
| Diphenhydramine | None | 13 | $74 | $6 |
2022: 13 drugs
| Octagam | Immune globulin | 74 | $1,501,732 | $20,294 |
| Gammagard Liquid | Immune globulin | 27 | $438,198 | $16,230 |
| Orencia | None | 63 | $251,693 | $3,995 |
| Inflectra | None | 18 | $74,975 | $4,165 |
| Actemra | None | 22 | $60,188 | $2,736 |
| Methotrexate | None | 81 | $4,156 | $51 |
| Mycophenolate Mofetil | None | 16 | $2,334 | $146 |
| Hydroxychloroquine Sulfate | None | 34 | $1,646 | $48 |
| Azathioprine | None | 24 | $1,375 | $57 |
| Prednisone | None | 78 | $962 | $12 |
| Methylprednisolone Acetate | None | 17 | $792 | $47 |
| Sodium Chloride | None | 52 | $465 | $9 |
| Alendronate | None | 31 | $157 | $5 |
2021: 16 drugs
| Octagam | Immune globulin | 76 | $1,381,654 | $18,180 |
| Gammagard Liquid | Immune globulin | 40 | $632,098 | $15,802 |
| Orencia | None | 51 | $194,421 | $3,812 |
| Inflectra | None | 22 | $83,255 | $3,784 |
| Renflexis | None | 11 | $40,135 | $3,649 |
| Methotrexate | None | 104 | $3,452 | $33 |
| Methylprednisolone Sodium Succ | None | 29 | $3,372 | $116 |
| Mycophenolate Mofetil | None | 16 | $2,262 | $141 |
| Hydroxychloroquine Sulfate | None | 38 | $2,156 | $57 |
| Azathioprine | None | 29 | $1,895 | $65 |
| Celecoxib | None | 15 | $1,473 | $98 |
| Prednisone | None | 97 | $1,361 | $14 |
| Diphenhydramine | None | 17 | $294 | $17 |
| Lidocaine | None | 13 | $172 | $13 |
| Gabapentin | None | 12 | $137 | $11 |
| Alendronate | None | 33 | $136 | $4 |
2020: 18 drugs
| Gammagard Liquid | Immune globulin | 41 | $634,483 | $15,475 |
| Gammaked | Immune globulin | 23 | $396,760 | $17,250 |
| Octagam | Immune globulin | 11 | $237,838 | $21,622 |
| Inflectra | None | 19 | $90,642 | $4,771 |
| Orencia | None | 17 | $72,185 | $4,246 |
| Remicade | None | 22 | $66,997 | $3,045 |
| Actemra | None | 19 | $66,390 | $3,494 |
| Xifaxan | None | 28 | $59,872 | $2,138 |
| Evenity (2 Syringes) | None | 12 | $23,687 | $1,974 |
| Methotrexate | None | 168 | $7,603 | $45 |
| Eliquis | None | 11 | $5,363 | $488 |
| Hydroxychloroquine Sulfate | None | 43 | $4,564 | $106 |
| Prednisone | None | 143 | $1,777 | $12 |
| Cevimeline | None | 12 | $1,240 | $103 |
| Celecoxib | None | 12 | $630 | $52 |
| Pregabalin | None | 13 | $598 | $46 |
| Alendronate | None | 56 | $402 | $7 |
| Gabapentin | None | 15 | $171 | $11 |
2019: 18 drugs
| Gammagard Liquid | Immune globulin | 43 | $738,876 | $17,183 |
| Panzyga | Immune globulin | 17 | $343,912 | $20,230 |
| Gammaked | Immune globulin | 26 | $340,423 | $13,093 |
| Orencia | None | 44 | $165,770 | $3,767 |
| Octagam | Immune globulin | 11 | $160,499 | $14,591 |
| Remicade | None | 30 | $159,653 | $5,322 |
| Actemra | None | 44 | $119,153 | $2,708 |
| Xeljanz | None | 15 | $69,470 | $4,631 |
| Xifaxan | None | 28 | $47,230 | $1,687 |
| Methotrexate | None | 128 | $5,102 | $40 |
| Eliquis | None | 11 | $4,942 | $449 |
| Hydroxychloroquine Sulfate | None | 32 | $3,427 | $107 |
| Prednisone | None | 146 | $2,471 | $17 |
| Sulfasalazine Dr | None | 17 | $1,589 | $93 |
| Neomycin Sulfate | None | 19 | $783 | $41 |
| Celecoxib | None | 18 | $620 | $34 |
| Amoxicillin-Clavulanate Potass | None | 17 | $523 | $31 |
| Alendronate | None | 37 | $290 | $8 |
2018: 16 drugs
| Xeljanz | 20 | $82,506 | $4,125 |
| Orencia | 22 | $81,652 | $3,711 |
| Actemra | 42 | $77,938 | $1,856 |
| Xifaxan | 31 | $50,602 | $1,632 |
| Methotrexate | 100 | $4,869 | $49 |
| Hydroxychloroquine Sulfate | 42 | $4,704 | $112 |
| Fluconazole | 11 | $3,270 | $297 |
| Potassium Chloride | 17 | $2,734 | $161 |
| Sulfasalazine Dr | 25 | $2,290 | $92 |
| Prednisone | 124 | $2,284 | $18 |
| Neomycin Sulfate | 25 | $1,058 | $42 |
| Celecoxib | 17 | $666 | $39 |
| Azathioprine | 16 | $636 | $40 |
| Amoxicillin-Clavulanate Potass | 17 | $471 | $28 |
| Alendronate | 16 | $160 | $10 |
| Quetiapine | 14 | $145 | $10 |
2017: 16 drugs
| Orencia | 29 | $102,816 | $3,545 |
| Actemra | 43 | $69,207 | $1,609 |
| Xifaxan | 34 | $52,898 | $1,556 |
| Methotrexate | 88 | $6,425 | $73 |
| Hydroxychloroquine Sulfate | 30 | $5,338 | $178 |
| Potassium Chloride | 19 | $3,526 | $186 |
| Fluconazole | 13 | $3,274 | $252 |
| Sulfasalazine Dr | 30 | $2,756 | $92 |
| Prednisone | 155 | $2,638 | $17 |
| Azathioprine | 22 | $1,505 | $68 |
| Neomycin Sulfate | 30 | $1,261 | $42 |
| Erythromycin | 12 | $836 | $70 |
| Metronidazole | 19 | $321 | $17 |
| Celecoxib | 12 | $238 | $20 |
| Alendronate | 19 | $148 | $8 |
| Quetiapine | 13 | $132 | $10 |
2016: 13 drugs
| Orencia | 37 | $125,430 | $3,390 |
| Actemra | 58 | $97,819 | $1,687 |
| Xifaxan | 27 | $35,637 | $1,320 |
| Hydroxychloroquine Sulfate | 37 | $8,516 | $230 |
| Methotrexate | 99 | $4,828 | $49 |
| Prednisone | 121 | $2,087 | $17 |
| Sulfasalazine Dr | 22 | $1,973 | $90 |
| Potassium Chloride | 13 | $1,522 | $117 |
| Celecoxib | 11 | $863 | $78 |
| Azathioprine | 15 | $617 | $41 |
| Alendronate | 21 | $130 | $6 |
| Quetiapine | 13 | $125 | $10 |
| Allopurinol | 17 | $65 | $4 |
2015: 14 drugs
| Actemra | 72 | $122,097 | $1,696 |
| Orencia | 27 | $101,863 | $3,773 |
| Hydroxychloroquine Sulfate | 27 | $8,185 | $303 |
| Methotrexate | 106 | $7,429 | $70 |
| Prednisone | 127 | $2,432 | $19 |
| Sulfasalazine Dr | 38 | $2,021 | $53 |
| Celecoxib | 13 | $1,228 | $94 |
| Azathioprine | 16 | $971 | $61 |
| Allopurinol | 35 | $305 | $9 |
| Ciprofloxacin | 13 | $144 | $11 |
| Alendronate | 20 | $141 | $7 |
| Naproxen | 11 | $113 | $10 |
| Alprazolam | 14 | $72 | $5 |
| Tramadol | 18 | $46 | $3 |
2014: 12 drugs
| Actemra | 69 | $111,633 | $1,618 |
| Methotrexate | 67 | $6,414 | $96 |
| Celebrex | 15 | $4,649 | $310 |
| Prednisone | 144 | $2,722 | $19 |
| Hydroxychloroquine Sulfate | 33 | $819 | $25 |
| Sulfasalazine Dr | 16 | $672 | $42 |
| Ketorolac Tromethamine | 14 | $297 | $21 |
| Alendronate | 32 | $193 | $6 |
| Allopurinol | 13 | $123 | $9 |
| Alprazolam | 18 | $120 | $7 |
| Triamcinolone Acetonide | 15 | $105 | $7 |
| Ondansetron | 12 | $100 | $8 |
2013: 15 drugs
| Actemra | 27 | $34,714 | $1,286 |
| Methotrexate | 111 | $7,378 | $66 |
| Prednisone | 120 | $1,612 | $13 |
| Doxycycline Hyclate | 14 | $1,225 | $87 |
| Hydroxychloroquine Sulfate | 27 | $833 | $31 |
| Sulfazine Ec | 14 | $806 | $58 |
| Azathioprine | 17 | $607 | $36 |
| Alendronate | 53 | $475 | $9 |
| Sulfasalazine Dr | 11 | $405 | $37 |
| Potassium Chloride | 13 | $190 | $15 |
| Triamcinolone Acetonide | 17 | $155 | $9 |
| Levothyroxine | 12 | $87 | $7 |
| Tramadol | 17 | $67 | $4 |
| Hydrocodone-Acetaminophen | 11 | $53 | $5 |
| Sodium Chloride | 12 | $33 | $3 |
Money from drug and device companies
$862 in 2025
| 2025 | 4 | 29 | None | $862 |
| 2024 | 1 | 13 | None | $218 |
| 2023 | 2 | 3 | None | $203 |
| 2022 | 1 | 2 | None | $57 |
| 2021 | 2 | 2 | None | $144 |
| 2020 | 1 | 1 | None | $14 |
| 2019 | 2 | 4 | None | $69 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Amgen | Krystexxa | $564 | 21 payments
|
| AstraZeneca Pharmaceuticals LP | Saphnelo | $144 | 6 payments
|
| GlaxoSmithKline | Benlysta | $122 | 1 payment
|
| Invivyd | Pemgarda | $33 | 1 payment
|
See all 29 published payments
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-19 | Saphnelo | $16 |
| Amgen | Meals · 2025-11-20 | Krystexxa | $30 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-13 | Saphnelo | $34 |
| Amgen | Meals · 2025-10-28 | Krystexxa | $44 |
| Amgen | Meals · 2025-10-14 | Krystexxa | $20 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-26 | Saphnelo | $21 |
| Amgen | Meals · 2025-09-24 | Krystexxa | $122 |
| Amgen | Meals · 2025-09-23 | Krystexxa | $11 |
| Amgen | Meals · 2025-09-23 | Otezla | $33 |
| Amgen | Education · 2025-07-31 | Krystexxa | $1 |
| Amgen | Meals · 2025-07-31 | Krystexxa | $28 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-30 | Saphnelo | $13 |
| Amgen | Meals · 2025-07-29 | Tavneos | $11 |
| Invivyd | Meals · 2025-07-10 | Pemgarda | $33 |
| Amgen | Meals · 2025-07-09 | Krystexxa | $14 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-08 | Saphnelo | $25 |
| Amgen | Meals · 2025-06-19 | Krystexxa | $30 |
| GlaxoSmithKline | Meals · 2025-05-28 | Benlysta | $122 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-15 | Saphnelo | $34 |
| Amgen | Meals · 2025-05-15 | Krystexxa | $29 |
| Amgen | Meals · 2025-05-08 | Tavneos | $4 |
| Amgen | Meals · 2025-04-24 | Krystexxa | $26 |
| Amgen | Meals · 2025-04-03 | Krystexxa | $31 |
| Amgen | Meals · 2025-03-13 | Otezla | $11 |
| Amgen | Meals · 2025-03-13 | Krystexxa | $32 |
| Amgen | Meals · 2025-02-20 | Krystexxa | $23 |
| Amgen | Meals · 2025-02-20 | Otezla | $28 |
| Amgen | Meals · 2025-01-30 | Krystexxa | $25 |
| Amgen | Meals · 2025-01-07 | Krystexxa | $11 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $218
| Amgen | Krystexxa | $218 | 13 payments
|
2023: $203
| Horizon Therapeutics plc | Krystexxa | $123 | 1 payment
|
| Amgen | Tavneos | $80 | 2 payments
|
2022: $57
| Amgen | Enbrel | $57 | 2 payments
|
2021: $144
| AstraZeneca Pharmaceuticals LP | Saphnelo | $126 | 1 payment
|
| Pfizer | Inflectra | $18 | 1 payment
|
2020: $14
| Pfizer | Xeljanz | $14 | 1 payment
|
2019: $69
| Pfizer | Inflectra | $47 | 3 payments
|
| Janssen Biotech | Simponi | $21 | 1 payment
|
Professional record
- NPI
- 1477656353
- Licence
- CA G28544California G28544: Current · expires 2027-05-31
- Trained
- University of California, San Francisco School of Medicine, 1973 · 53 years ago
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Medicaid ID
- CA 00G285440
- Taxonomy
- Federal specialty code 174400000X (174400000X)
- Mailing address
- 18350 Roscoe Blvd, Suite 418, Northridge, CA, 91325
- NPI first listed
- 2006-09-06
- NPI last updated
- 2023-06-30
- NPI record certified
- 2023-06-30
This is when the NPI record was last certified, not a medical board exam.